← Back to headlines
BMO Raises Price Target for Protagonist Therapeutics on Drug Approval
Investment analysts have increased their valuation forecast for Protagonist Therapeutics following regulatory approval for its Mimrylo treatment.
1 Sept, 14:00 — 1 Sept, 14:00
Sources
Showing 1 of 1 sources
Related Stories
US Considers Targeted Chip Tariffs Amid Trade Discussions With Mexico
25m ago
OPEC+ Expected to Maintain Current Oil Production Quotas
31m ago
New York City Public Schools Ban Artificial Intelligence for Students Through Eighth Grade
34m ago
Uber and Wayve Launch Driverless Robotaxi Service in London
1h ago